NYSE · Healthcare · Drug Manufacturers - General · USA
Johnson & Johnson is a mega cap company (market value over $200 billion) in the Drug Manufacturers - General industry.
Johnson & Johnson is a holding company that researches, develops, manufactures and sells healthcare products worldwide. The company operates through two segments: Innovative Medicine, which offers pharmaceutical treatments across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular areas; and MedTech, which produces cardiovascular, orthopaedic, surgical and vision products for hospitals and physicians.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Johnson & Johnson stock.
Overvalued: intrinsic value $199.15 per share, market price $253.79, margin of safety -27.4% (as of 2026-10-19).
Discounting its cash flows at 7.1% (average of 3 methods) values the shares at $199.15; the price of $253.79 is 27% above that value, and 83% of that value comes from beyond year five.
Leak Score: 48/100 on 11 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
3 more in this industry show a wider margin of safety.
JNJ is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 7.1% (average of 3 methods) values the shares at $199.15; the price of $253.79 is 27% above that value, and 83% of that value comes from beyond year five.
$199.15 per share (as of the 2026-10-19 close), against a market price of $253.79. That is a margin of safety of -27.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for more growth than the company has delivered. It needs the future to beat the past. Yearly sales growth the price needs: 14.9%. Yearly sales growth it has sustained: 6.0%.
48 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.